key: cord-0763009-coyin6tj
authors: Ramoni, Rachel; Klote, Molly; Muralidhar, Sumitra; Brandt, Cynthia; Bernstein, Maya A; McMahon, Benjamin H; Jacobson, Daniel A; Justice, Amy C
title: COVID-19 Insights Partnership: Leveraging Big Data from the Department of Veterans Affairs and Supercomputers at the Department of Energy under the Public Health Authority
date: 2021-03-29
journal: J Am Med Inform Assoc
DOI: 10.1093/jamia/ocab062
sha: c852cf47869c26eaeb787be4338c15e210c666fe
doc_id: 763009
cord_uid: coyin6tj

nan

Laboratory (ORNL) where datasets from multiple federal agencies can be brought together and combined for public health research purposes. With appropriate regulation, data governance and data access policies in place, qualifying investigators from multiple federal agencies will be able to combine DOE's high-performance computing and artificial intelligence expertise with national longitudinal electronic health record data from veterans as well as health data from non-veterans diagnosed with COVID-19 [1] [2] [3] [4] [5] . This research will bolster the nation's ability to understand, prevent, and treat COVID-19 and will better position the nation to respond to future public health emergencies.

This advance would not have been possible without two interagency programs.

The first began before COVID-19. In 2016, VA and DOE formed an interagency collaboration known as Computational Health Analytics for Medical Precision to Improve Outcomes Now (CHAMPION) to demonstrate the power of combining VA's health record system, Million Veteran Program (MVP) genetic data, and clinical research expertise with DOE's high-performance computing infrastructure and artificial intelligence expertise. The second occurred as part of the Insights Partnership in direct response to the pandemic. This was a novel application of the public health authority already invested within HHS to allow for sharing of health data among federal agencies for purposes that support public health. The use of this public health authority set the stage for collaboration not only for the current pandemic but also for future national health emergencies, and for ongoing concerns such as suicide prevention or cancer care.

As of this writing, SARS-CoV-2 vaccines have been brought from conception to mass deployment in under twelve months. Similarly, the case fatality rate (confirmed COVID deaths/confirmed COVID cases) has decreased from ~7% to ~1%, through a combination of case-load reduction and improved clinical practice. Yet many critical public health questions remain. These concern epidemiological situational awareness and disease transmission and manifestation that can best be answered through data integration across clinical, pathophysiological, disease mechanism, epidemiological, and decision-support perspectives. Some examples include: 

Drawing upon the expertise of the regulatory and privacy community, the authors and their collaborators came to the conclusion that use of the HHS public health authority would make such sharing possible with the least burden and highest data quality while still preserving the privacy of the record subjects. While many researchers had previously considered combining individually-identifiable health information covered by the Health Insurance Portability and Accountability Act (HIPAA) across federal agencies, no group had ever found a viable pathway. This partnership represents a first in that regard. The heart of the partnership is a memorandum of understanding signed by HHS, VA, and DOE. The Partnership plans additional data-use agreements for the future.

Each agency plays a unique and critical role: HHS will establish the COVID-19

Insights Collaboration Records Database to support understanding and tracking of SARS-CoV-2 and responses to COVID-19 outbreaks. DOE will maintain this database for HHS at its Oak Ridge National Laboratory (ORNL) in Tennessee. The Relying on the public health authority permitted the integration of records sets and analytic tools in a privacy appropriate environment. Protected health information (PHI) that is collected by the federal government is restricted from sharing without patient authorization by privacy laws and regulations except in limited circumstances.

Use of the public health authority is one of those exceptions. The agencies are also establishing a new "system of records" under the Privacy Act with a public notice in the Federal Register, preparing a privacy impact assessment under the E-Government Act, and have concluded data use agreements to set the rules for data sharing and retention.

The NSC has formed the COVID Insights Task Force to oversee the partnership's work. The task force has representatives of VA, HHS, DOE, and NSC.

The task force initially met daily and now meets twice a week to review requests from FDA for analyses to address related public health questions of national importance. The task force determines the priority level of each request based on the latest trends in the COVID-19 pandemic, and it has the authority to determine which analyses will be conducted.

The collaboration has produced a cadre of VA and DOE scientists familiar with VA patient data and experienced in conducting joint research successfully. It is also leading to the integration of omics data with clinical data for a better mechanistic understanding of COVID-19 pathogenesis and potential therapies. Because of this collaboration between VA and DOE, interagency teams were prepared at the start of the COVID-19 pandemic to develop the required agreements 1,3,4,5 .

The COVID-19 Insights Collaboration Records Database will only have data deemed necessary by the Task Force to address COVID-19 pandemic questions.

Although HHS will have ultimate responsibility for the dataset, VA and any other agencies contributing data expect that the data will not be used for purposes beyond SARS-CoV-2 or COVID-19 public health activities.

The database resulting from the combination of records may contain personally identifiable information but is not designed to maintain direct identifiers such as names or social security numbers. The HIPAA Privacy Rule allows PHI to be disclosed from a covered entity, such as VHA, for public health activities to a public health authority, such as HHS. In addition, while in the custody of VHA, the records are covered by the Privacy Act of 1974, and require a separate authority to disclose under that law. The Privacy Act permits a federal agency to disclose Privacy Act records to parties outside the agency without the consent of the individual record subjects, for purposes compatible with the records' original collection purpose by establishing such a disclosure through an administrative process. The resulting disclosure is known by a term of art in the Privacy Act as a "routine use." To ensure the safety and confidentiality of the database, VA is storing its data in a high-security computing facility in the United States. Other federal agencies that contribute data will also have this option. An Institutional Review Board (IRB) must review and approve all partnership studies to ensure that potential ethical and regulatory concerns are addressed. The uses of the partnership data are similar to the ways in which health care systems use their own data to conduct chart reviews and other retrospective studies with IRB approval and a waiver of HIPAA authorization.

VA has recommended to HHS that all data released from the COVID-19 Insights Collaboration Records Database be deidentified (per the HIPAA definition) and that investigators from federal agencies (other than DOE) or other institutions that have not provided data never have an opportunity to view identifiable forms of the data.

The COVID-19 Insights Partnership hopes to combine data on care provided to veterans inside and outside VA. This enables investigators from any Agency contributing data to understand the pandemic in new ways by bringing together data on health care received by veterans before, during, and after each COVID-19 episode. The partnership can also more efficiently identify modifiable mediators of COVID-19 health care outcomes and design appropriate interventions to address them. An important goal is to create generalizable knowledge from the data for translation beyond the VA population.

Using previously established inter-agency agreements and data governance, the partnership has already conducted research showing that the bradykinin storm is likely to play a role in many COVID-19 symptoms 1 and, using VA data, compared COVID-19 testing patterns, positive test results, and 30-day mortality rates by race and ethnicity among VA patients. 2 Other recently completed studies have developed and validated short-term mortality indices in individuals with COVID-19 based on their preexisting conditions 3 , assessed the generalizability of VA COVID-19 experiences to the U.S. population, and evaluated the effectiveness of hydroxychloroquine with and without azithromycin in VA patients with COVID-19. The most recent study demonstrates the benefit of prophylactic anticoagulation at initial hospitalization. 5 Ongoing studies are evaluating experiences with steroid therapies, with antibody tests, and, in collaboration with CDC, beginning to explore the long-hauler syndrome. As COVID-19 infections continue, the partnership will conduct public health analyses on the longer-term complications of this infection as well as on a "steady state" approach to curbing infection that will include vaccination programs. pandemic as well as to the inevitable next epidemic, especially to protect those who are most vulnerable. The partnership will help determine how new artificial intelligence techniques can best complement traditional statistical and epidemiologic methods for real-world data analyses. Efforts will also be needed to ensure rapid implementation of the lessons from this partnership. This regulatory pathway for sharing data under the HIPAA Privacy Rule's public health authority should be considered in any ongoing or future public health emergency with HHS support. The ability to leverage medical data from federal datasets to address critical public health questions developed through the COVID-19 Insights Partnerships will be valuable in the future whenever the nation faces a rapidly evolving epidemic or other public health emergency.

acknowledges that the United States Government retains a nonexclusive, paid-up, irrevocable, world-wide license to publish or reproduce the published form of this manuscript, or allow others to do so, for United States Government purposes. The Department of Energy will provide public access to these results of federally sponsored research in accordance with the DOE Public Access Plan 

A mechanistic model and therapeutic interventions for COVID-19 involving a RAS-mediated bradykinin storm

Patterns of COVID-19 testing and mortality by race and ethnicity among United States veterans: A nationwide cohort study

Development and validation of a 30-day mortality index based on preexisting medical administrative data from 13,323 COVID-19 patients: The Veterans Health Administration COVID-19 (VACO) Index

Attacking the opioid epidemic: Determining the epistatic and pleiotropic genetic architectures for chronic pain and opioid addiction

Early initiation of prophylactic anticoagulation for prevention of COVID-19 mortality: a nationwide cohort study of hospitalized patients in the United States

The 

None of the authors have any competing interests to declare.

All authors made substantial contributions to the conception of the work, participated in revising the manuscript for important intellectual content and have approved the final version of the manuscript. All questions related to the accuracy or integrity of any part of the work have been appropriately investigated and resolved. ACJ is the corresponding author.

This manuscript has been coauthored by UT-Battelle, LLC under contract no.